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The antimalarial drugs artemisinins have been described as
inhibiting Ca2-ATPase activity of PfATP6 (Plasmodium falcipa-
rum ATP6) after expression in Xenopus oocytes. Mutation of an
amino acid residue inmammalian SERCA1 (Glu255) to the equiva-
lent one predicted in PfATP6 (Leu) was reported to induce sensi-
tivity to artemisinin in the oocyte system. However, in the present
experiments,wefoundthatartemisinindidnot inhibitmammalian
SERCA1a E255L either when expressed in COS cells or after puri-
fication of the mutant expressed in Saccharomyces cerevisiae.
Moreover,we found thatPfATP6after expressionandpurification
from S. cerevisiae was insensitive to artemisinin and significantly
less sensitive to thapsigargin and 2,5-di(tert-butyl)-1,4-benzo-
hydroquinone than rabbit SERCA1 but retained higher sensitivity
to cyclopiazonic acid, another typeof SERCA1 inhibitor.Although
mammalian SERCA and purified PfATP6 appear to have different
pharmacological profiles, their insensitivity to artemisinins sug-
gests that the mechanism of action of this class of drugs on the
calcium metabolism in the intact cell is complex and cannot be
ascribed to direct inhibition of PfATP6. Furthermore, the success-
ful purification of PfATP6 affords the opportunity to develop new
antimalarials by screening for inhibitors against PfATP6.
Malaria is a major infectious disease with about 500 million
cases and onemillion deaths every year. Humanmalaria is caused
by five species of protozoan parasites of the genus Plasmodium
transmitted to humans by female Anopheles mosquitoes. Infec-
tions with Plasmodium falciparum are responsible for the most
severe disease and deaths. Without a vaccine, drug treatment is a
critical part of malaria control strategies. However, drug-resistant
parasites are severely compromising the effectiveness of many
therapies (1, 2). The artemisinins have maintained their efficacy
despite the emergence of drug resistance to other classes of anti-
malarial drugs, although even this class now exhibits clinically rel-
evant resistance in someareas (3).Artemisininskill parasites faster
(4) andwith less toxicity (5) thanotherdrugs, but theirmechanism
of action is not yet clearly known. Artemisinin is extracted from
Artemisia annua, an herb long used to treat fevers in traditional
Chinese medicine, and derivatives have been developed to
improve their potency, solubility, stability, and pharmacokinetic
properties (6–9). Artemisinins are sesquiterpene trioxane lac-
tones that contain an endoperoxide bridge essential for antimalar-
ial activity (10). They are effective against the blood stages of
Plasmodium and especially the early ring and sexual stages (game-
tocytes) of theparasite life cycle (4, 11, 12).Artemisinins andderiv-
atives accumulate preferentially in infected erythrocytes (13, 14)
and are mainly located in parasite membranes and their neutral
lipids, where the accumulation patterns are endoperoxide-depen-
dent (15, 16). The generation of free radicals by artemisinins may
be critical for killing parasites, an observation that is consistent
with the importance of the endoperoxide bridge for drug efficacy
(17). The nature of these radicals and how they are generated is
debated, with hypotheses including roles for iron- or heme-cata-
lyzing Fenton-like reactions (18, 19).
Artemisinin inhibits the endocytosis of red blood cell cytoplas-
mic macromolecules by the parasite (20), possibly via an increase
in the cytosolic level of Ca2. Efficacy against Toxoplasma gondii
has also been related to changes in calcium homeostasis in this
member of the apicomplexan family of parasites that includes
Plasmodium spp. (21, 22). Several P-typeATPases (PfATP6, a sar-
co(endo)plasmic reticulum calcium ATPase (SERCA)4-type pro-
tein; PfATP4, a PTM (plasma membrane ATPase-related)-like
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protein; and three putative ATPases that seem to belong to the
Golgi-endoplasmic reticulum-type family) and a single Ca2/H
exchanger were identified to be involved in the maintenance of
calcium homeostasis in P. falciparum (23).
Recently, Krishna and co-workers (24–26) observed that the
ATPase activity of the single SERCA of P. falciparum, PfATP6,
expressed in Xenopus laevis oocyte was inhibited by artemisinin
(Ki150 nM). Isobologram analysis and competition studies with
fluorophore derivatives localizing to parasites were consistent
with a common target for artemisinin and thapsigargin (Tg), a
specific inhibitor of SERCA-type proteins, because an antagonism
was observed in the action of these drugs. PfATP6 and SERCA1
share an overall 40% identity with a well conserved transmem-
brane region,whereas the cytosolic sequenceof theparasiteCa2-
ATPase contains about 200 additional residues. Mutation studies
on PfATP6 expressed in oocytes suggested that, in particular,
Leu263modulates the sensitivityof this enzymetoartemisinin (26).
This experiment was in part based on the finding that rabbit
SERCA1,whoseTgbinding site isnearPhe256 (27), is insensitive to
artemisinin, and its amino acid sequence contains at the homolo-
gous position of Leu263 a glutamate (Glu255). When the Leu263 of
PfATP6 was mutated to glutamate, sensitivity to artemisinin was
decreased (26), and conversely when the glutamate residue of
SERCA1 was mutated to a leucine, SERCA1 became sensitive to
artemisinin (26). These results suggest that PfATP6 is a target for
artemisinins, with further support derived from correlation
between certain pointmutations in PfATP6 in field isolates show-
ing reduced in vitro sensitivity to artemether (28) and dihydroar-
temisinin (29), although all of the cases of artemisinin resistance
are not related to these mutations but revealed some polymor-
phism (3, 19, 30, 31).
Up to now, only two of these transporters (PfATP6 and
PfATP4) and mutated SERCA1a E255L have been studied in the
X. laevisoocyte system(24, 26, 32). Inorder to further examine the
interaction of artemisinins with PfATP6 and SERCA1a E255L
mutant, it is important to characterize inmore detail (functionally
and structurally) those Ca2-ATPases. For that purpose, expres-
sion in alternative systems (we investigatedCOS-1 and yeast cells)
and purification of the proteins is required. Our group recently
developed amethod to purify rabbit SERCA1a by affinity chroma-
tography after its expression in yeast (33), and this method was
successfully used for studying and crystallizing wild type (34) and
mutated SERCA1a (35). In the present study, yeast expressionwas
applied to purify and functionally characterize SERCA1a E255L
andPfATP6andtostudy theeffectsof artemisininandotherdrugs
when combined with detergent or lipids.
EXPERIMENTAL PROCEDURES
Chemicals—All chemical products were purchased from
Sigma unless specified otherwise. PfuTurboDNA polymerase
was from Stratagene, and Electroelution G-capsules were from
G-Biosciences (AGRO-BIO, La Ferte´ Saint Aubin, France).
Phusion high fidelity polymerase was from Finnzymes
(Ozyme, Saint Quentin en Yvelines, France). Restriction and
modification enzymes were from New England Biolabs
(Ozyme, Saint Quentin en Yvelines, France). High activity
bovine thrombin was from Calbiochem, and the streptavidin-
SepharoseTM High Performance was purchased from GE
Healthcare. All products for yeast and bacteria cultures were
purchased from Difco (BD Biosciences). 1,2-Dioleoyl-sn-glyc-
ero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phosphoserine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
ethanolamine, and egg yolk phosphatidylcholine were from
Avanti Polar Lipids (Alabaster, AL); L--phosphatidylinositol
from soybean (catalog no. P0639) was from Sigma.N-Dodecyl-
-D-maltoside (DDM) was from Anatrace (Maumee, OH), and
octaethylene glycol mono-n-dodecyl ether (C12E8) was pur-
chased fromNikkol Chemical (Tokyo, Japan). Precision protein
standards were from Bio-Rad. Immobilon-P membranes were
from Millipore (Bedford, MA). Avidin-peroxidase conjugate
was from Sigma. Phosphoenolpyruvate (catalog no. P3637),
L-lactic dehydrogenase solution from bovine heart (catalog no.
L1006), and pyruvate kinase preparation type VII from rabbit
muscle (catalog no. P7768) were from Sigma.
COS-1 Cell Experiments—Site-directed mutagenesis of
cDNA encoding SERCA1a inserted into the pMT2 vector (36)
was carried out using the QuikChange site-directed mutagen-
esis kit (Stratagene), and the mutant cDNA was sequenced
throughout. To express wild type or E255L mutant cDNA,
COS-1 cells were transfected using the calcium phosphate pre-
cipitation method (37). Microsomal vesicles containing the
expressed proteins were isolated by differential centrifugation
(38). The concentration of expressed Ca2-ATPase was deter-
mined by an enzyme-linked immunosorbent assay (39) and by
determination of the maximum capacity for phosphorylation
with ATP (“active site concentration”; see Ref. 40). ATPase
activity was determined by following the liberation of Pi (41) in
the presence of 4 M calcium ionophore A23187 to prevent
inhibition caused by rebinding of Ca2 to the luminally facing
Ca2 sites (40). Inhibition assays were performed at 25 °C or
37 °C by first preincubating microsomal vesicles together with
the drug over an 8-min period and then measuring the ATPase
activity for 10 or 30 min, respectively.
Yeast Transformation and Selection of Individual Clones—
The Saccharomyces cerevisiae yeast strain W303.1b/Gal4 (a,
leu2, his3, trp1::TRP1-GAL10-GAL4, ura3, ade2-1, canr, cir)
was the same as previously described (42). Transformation was
performed according to the lithium acetate/single-stranded
carrier DNA/polyethylene glycol method (43). Growth condi-
tions and criteria for expression of the Ca2-ATPase were car-
ried out as described for the test of individual clones and for the
expression on minimal medium (42, 44). A colony streaked
onto a minimum medium storage plate was toothpicked into
minimum medium (0.1% bactocasamino acids, 0.7% yeast
nitrogen base, 2% glucose (w/v), 20 g/ml adenine) and grown
at 28 °C for 24 h with shaking (200 rpm). For each assay, 500 l
of the minimum medium precultures were centrifuged for 5
min at 4 °C and 1000  gav (rotor AM2.19, Jouan MR22i) and
resuspended in 5 ml of minimum medium with 2% galactose
instead of glucose to induce expression. These cultures were
incubated at 28 °C for 18 h with shaking. For each culture, 4
A600 nmwere centrifuged for 5min, at 4 °C and 8000 gav. After
washing with water, the pellets were resuspended in cooled 2%
trichloroacetic acid. Glass beads were added, and the suspen-
sions were mixed with a vortex at maximal speed for 8 min at
room temperature to break the cells. The tubes were then
SERCA Pumps and Artemisinin
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placed on ice, and glass beads were sedimented. The superna-
tant was kept on ice. After three washes with 2% trichloroacetic
acid, all of the collected supernatants were gathered. The
resulting solution was kept for 15min on ice for protein precip-
itation. Then the samples were centrifuged for 15 min, at 4 °C
and 30,000 gav. The pellets were resuspended in 100 l of 50
mM Tris-Cl, pH 7.5. These samples were analyzed by Western
blotting after SDS-PAGE in order to choose which clones were
best expressed.
Expression of SERCA1a E255L in Fernbach Flasks—Growth
conditions of yeast and induction of the expression of the
mutant were the same as previously published for native
SERCA1a expressed in yeast (33).
Growth of Yeast Cells and Large Scale Expression of PfATP6
Using a Fermentor (Techfors-S Apparatus, INFORS HT, Massy,
France)—This method is based on the one developed for
SERCA1a in Fernbach flasks with the following modifications:
20 liters of YPGE2X were inoculated with 1.2 liters of a culture
at exponential phase inminimummedium (6 106 cells/ml).
Culture was performed at 28 °C under high aeration (1 volume
of air/volume/min; stirring rate 300 rpm) at the beginning of
the culture and then regulated to maintain a dioxygen satura-
tion of 20% until the cell density reached 3 108 cells/ml. The
culture was then cooled to 18 °C, the regulation of dioxygen
saturation was stopped, and stirring rate wasmaintained at 300
rpm, but aeration was lowered to 0.15 volume of air/volume/
min. Thirty minutes later, a solution of sterile galactose (500
g/liter) was added to a final concentration of 20 g/liter, and the
culture was continued for 13 h (45).
Preparation of Light Membrane Fractions—The light mem-
brane (LM) fractionwas obtained after breaking yeast cells with
glass beads and differential centrifugation of the crude extract
as described previously (42). They were finally resuspended in
Hepes-sucrose buffer (20 mM Hepes-Tris (pH 7.5), 0.3 M
sucrose, 0.1 mM CaCl2, 1 mM phenylmethylsulfonyl fluoride) at
a final volume corresponding to 0.5 ml/g of the initial yeast
pellet. The membranes can be stored at 80 °C until use. The
amount of the protein of interest is estimated by Western blot
analysis using the appropriate antibody.
Solubilization and Batch Purification of PfATP6 by Strepta-
vidin-Sepharose Chromatography—These procedures are
described in the supplemental material.
Protein Estimation and Ca2-ATPase Quantification—Pro-
tein concentrations were measured by the bicinchoninic acid
procedure (46) in the presence of 2% SDS (w/v) with bovine
serum albumin as a standard. SERCA1a from rabbit muscle
(SR), used as a standard for protein estimation, was prepared as
previously described (47). Ca2-ATPase quantification was
performed either by a Coomassie Blue staining gel after SDS-
PAGE or Western blot using known amounts of SR as
standards.
SDS-PAGE and Western Blotting—For SDS-PAGE, samples
were mixed with an equal volume of denaturing buffer, heated
at 90 °C for 2 min, and loaded onto Laemmli-type 8% (w/v)
polyacrylamide gels (48). The amounts of proteins or volumes
of initial samples loaded in each well are indicated in the figure
legends. After separation by SDS-PAGE, gels were stained with
Coomassie Blue, or proteins were electroblotted onto polyvi-
nylidene difluoride Immobilon P membrane (49). For each gel,
molecularmassmarkers (Precision Protein standards, Bio-Rad)
were loaded.
TheWestern blotting was followed by detection with avidin-
peroxidase for the recognition of biotinylated proteins or by
immunodetection with the polyclonal antibody anti-SERCA1a
79B (a gift from A.-M. Lompre´, INSERM, France) as described
previously (33).
Immunodetection with Anti-PfATP6—For immunodetection
with anti-PfATP6 antibody, the polyclonal antibody anti-
PfATP6 generated in goat from the peptide CQSSNKKDK-
SPRGINK (the sequence from Q to K corresponds to the 574–
588 region of PfATP6) was used. Anti-PfATP6 antibodies were
purchased from Bethyl Laboratories. After electroblotting,
membranewas blocked for 10min in PBST (90mMK2HPO4, 10
mM KH2PO4 (pH 7.7), 100 mM NaCl, 0.2% (v/v) Tween 20)
containing 5% powdered skim milk. The primary antibody
(1:10,000) was then added to the solution and incubated for 1 h
at room temperature. The membrane was washed once for 10
min in PBST and then incubated with horseradish peroxidase-
conjugated secondary rabbit anti-goat antibody (1:10,000) in
PBST containing 5% powdered skim milk. After three washes
with PBST for 10 min each, detection of proteins was per-
formed with ECL (GE Healthcare). The chemiluminescence
signal was acquired with a GBoxHR 16 apparatus coupled with
GeneSnap acquisition software and analyzed with GeneTools
analysis software (Syngene, Ozyme, France).
Preparation of Lipids—Phospholipids dissolved in chloro-
form were dried in a stream of nitrogen. Dried phospholipids
were then dissolved at 5 mg/ml in C12E8 (20 mg/ml).
Detergent Removal and Relipidation—After purification and
before glycerol concentration adjustment, PfATP6was concen-
trated with the aid of a 100 kDa cut-off concentrator unit (Cen-
tricon YM100, Millipore). Egg yolk phosphatidylcholine was
then added to concentrated PfATP6 at a final concentration of
1mg/ml and a lipid/protein ratio of 3:1 (w/w). To remove deter-
gent, Bio-beads SM2, prepared as described (50), were added to
the solution at a Bio-beads/detergent ratio of 200:1 (w/w), and
the whole solution was gently stirred at 18 °C for 3 h. Bio-beads
were then removed, and the solution was kept at 4 °C.
ATPase ActivityMeasurement—ATPase activity was assayed
using a spectrophotometric method as described (51, 52). In
general, from 1 to 10g of proteins was used in 2ml of reaction
buffer (50mMTes/Tris, pH 7.5, 0.1 M KCl, 6mMMgCl2, 0.3mM
NADH, 1 mM phosphoenolpyruvate, 0.1 mg/ml lactate dehy-
drogenase, 0.1 mg/ml pyruvate kinase containing 0.1 mM Ca2
and 0.2:0.05 mg/ml C12E8/DOPC). Changes in reaction condi-
tions, detergents, amount of proteins, and variations in reaction
temperature are indicated in the figure legends. The reaction
was started by the addition of 5 mM ATP to the medium and
stopped by the addition of a final concentration of 750 M
EGTA. The difference between the slopes obtained before and
after the addition of EGTA is considered to be due to the Ca2-
ATPase activity. To obtain the specific activity, the concentra-
tion of Ca2-ATPase (SERCA1a E255L or PfATP6) was deter-
mined from Coomassie Blue-stained gels after SDS-PAGE.
Inhibition Assays—The inhibition assays were performed by
enzymatic spectrophotometry as described above except for
SERCA Pumps and Artemisinin
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vanadate because this inhibitor oxidizes NADH in a coupled
enzyme system (see supplemental material).
The drugs used (stock solutions at 15 mM Tg, 20 mM 2,5-
di(tert-butyl)-1,4-benzohydroquinone (BHQ), 3 mM cyclopia-
zonic acid (CPA), 10mMartemisinin, 10mMartemisone, and 10
mMdihydroartemisinin) were dissolved inDMSO.The effect of
DMSO alone was taken into account, and we corrected for it
when calculating the specific effect of the inhibitors.
All of the inhibition assays were performed by the addition of
2 l of each drug solution. The effect of inhibitors was investi-
gated by adding them during the ATPase turnover. In some
experiments, the protein was preincubated with these drugs for
a few min (but longer incubations were not more efficient)
before theATP addition, which triggers the start of the reaction
(as explained in the figure legends).
Because Fe2 ions were sometimes used in the assays, a 10
mMFeSO4 solutionwas freshly prepared and kept on ice (53). In
some cases, we also used Fe2 in the presence ofmetal chelators
as suggested (54).
RESULTS ANDDISCUSSION
Enzymatic Properties of the SERCA1a E255L Mutant
Expressed in COS-1 Cells—We found that the SERCA1a E255L
mutant, previously reported as being sensitive to artemisinin
(26), could be expressed in COS-1 cells to a level similar to that
of the wild type protein. To estimate the catalytic turnover of
the expressed proteins, we measured the maximum rate of
Ca2-activated ATP hydrolysis in the presence of the calcium
ionophore A23187 to avoid the “back inhibition” imposed by
Ca2 accumulated in the microsomal vesicles. The catalytic
turnover rate of SERCA1a E255Lmutant calculated by relating
the ATPase activity to the maximal phosphorylation capacity
was very similar to that of wild type, in agreement with earlier
experiments showing that mutation of Glu255 by Ala or His
does not affect maximal turnover (55). The inhibition by thap-
sigargin, a specific inhibitor of SERCA proteins (56), was nearly
complete for both wild type and E255Lmutant (Fig. 1,Tg). This
result indicates, on one hand, that the turnovers measured are
the result of the expressed Ca2-ATPases and, on the other
hand, that Glu255 does not play a decisive role for thapsigargin
sensitivity despite the fact that this residue is located at the
binding site (27). Then we measured the effect of artemisinin
alone or together with Fe2 because it was suggested that arte-
misinin could require the presence of iron to be an efficient
inhibitor (24). Both in the presence and absence of Fe2, there
was no inhibitory effect of artemisinin, even at high drug con-
centration (Fig. 1, ART and ARTFe2).
Study of the Mutant SERCA1a E255L and Purification and
Enzymatic Properties after Yeast Expression—The yeast light
membranes containing the SERCA1a E255Lmutant (endoplas-
mic reticulum and secretion vesicles) were prepared by mem-
brane fractionation, as described previously (33). From1 liter of
culture containing about 35 g of yeast, 325 mg of membrane
proteins with the SERCA1a E255L mutant was obtained in the
light membrane fraction. The subsequent solubilization with
DDM and tag-mediated affinity purification by streptavidin
chromatography were performed as described (35). After
thrombin cleavage, only SERCA1a E255L devoid of tag was
eluted from the resin, leading to the recovery of 150 g of
mutated protein at a concentration of about 30 g/ml as deter-
mined by Coomassie Blue gel staining and Western blotting
(see Fig. 2,A and B). The protein was well purified, as shown by
the Coomassie Blue-stained gel (to about 70%, most of the
impurity being due to phenylmethylsulfonyl fluoride-inhibited
thrombin; Fig. 2A).
To determine the effect of artemisinin on the purified
SERCA1a E255L mutant, the specific ATPase activity of the
protein was measured spectrophotometrically by a coupled
enzyme system. We found that the maximal rate of ATP
hydrolysis of the SERCA1a E255L mutant was slightly smaller
than the specific activity of the wild type SERCA1a protein,
overexpressed in yeast and measured under the same condi-
tions. The wild type SERCA1a has the same specific activity as
the wild type enzyme isolated from rabbit sarcoplasmic reticu-
lum, indicating that yeast expression and purification is a valid
method to study SERCA proteins (34), as also later confirmed
for mutants of that protein (35). The Ca2-dependent ATPase
activity of the mutant, like that of the wild type, could be
stopped both by thapsigargin (a specific inhibitor for SERCA-
type ATPases) and by EGTA (chelating agent of calcium ions)
(Fig. 2C, experiment A), supporting the suggestion that the
main calcium pumping function of this protein is retained in
themutant. To perform the assay under optimal conditions, we
have adopted the use of lipid/detergentmixtures. The presence
of DOPC in the assay media, forming mixed micelles with
C12E8, increased both the stability and enzymatic activity of
solubilized Ca2-ATPase. We found that optimal conditions
were obtained in the presence of 0.2 mg/ml C12E8 and 0.05
mg/ml DOPC (Fig. 2C, experiment B), and this resulted in a
large increase of the specific activity (Fig. 2C, compare experi-
ment B and experiment A). The phospholipid-dependent
increase in activity of purified P-typeATPases had already been
FIGURE 1. Effect of drugs onCOS-1 cell-expressed SERCA1awild type and
E255Lmutant. The rate of Ca2-activated ATP hydrolysis was determined at
25 °C in thepresenceof 4MCa2 ionophoreA23187 in amediumcontaining
50 mM TES/Tris (pH 7.0), 100 mM KCl, 7 mM MgCl2, 1 mM EGTA, 0.9 mM CaCl2
(giving a free Ca2 concentration of 3M), and 5mMATP. The effect of 1.5M
Tg, 10Martemisinin (ART), and 10Martemisinin togetherwith 10MFeSO4
(ARTFe2) were tested onwild type SERCA1a (black bars) and E255Lmutant
(open bars). The inhibitor was added dissolved in DMSO, giving a final DMSO
concentration of 5% (v/v), and turnover rates are shown as a percentage of
the turnover rate measured when the same amount of DMSO was added
without inhibitor. S.E. values are indicated by the error bars on the columns.
SERCA Pumps and Artemisinin
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observed (see Ref. 58, with the Na/K ATPase as a recent
example). The addition of artemisinin to the SERCA1a E255L
mutant solubilized in phospholipid/C12E8 medium did not
inhibit Ca2-ATPase activity (Fig.
2C, experiment C). The effect of
artemisinin in the presence of iron
(Fe2) was also tested (Fig. 2C,
experiment E) and compared with
the effect of iron alone (Fig. 2C,
experiment D). There was no inhib-
itory effect of artemisinin and iron
on the SERCA1a E255L mutant
ATPase activity, whereas the com-
bination gave rise to a slight increase
in activity.
On the basis of these results and
the results obtained with micro-
somes of COS-1 cells expressing the
same mutant, we were unable to
confirm that the mutation of Glu255
to Leu in SERCA1a determines
the sensitivity to artemisinin, as
described previously after expres-
sion of E255L SERCA1a mutant in
oocyte (26). There is thus no evi-
dence for an artemisinin binding
site with a putative localization in
the binding region for thapsigargin
on SERCA1a.
Study of PfATP6andExpression and
Purification of PfATP6 in Yeast—
Because in our hands the expression
of PfATP6 in COS-1 cells was not
successful, as previously reported (24), we then proceeded to
investigate the expression of that plasmodial protein PfATP6 in
yeast. Production of PfATP6 using an assay of expression on
minimal medium as described under “Experimental Proce-
dures” was attempted in parallel from the wild type and a
codon-optimized gene (the gene of PfATP6was the same as the
one used in Refs. 24 and 26). Although the codon adaptation
index (which is ameasure of the similarity of the codon usage of
a gene to that of the proposed host organism (59)) is high
(0.843) for the wild type PfATP6 gene and S. cerevisiae, we
designed a sequence that took into account optimal codon
usage for yeast and removed most of the poly(A) or T tracts in
the native sequence. Gene optimization increased the codon
adaptation index to a very high value (0.959) while leaving the
GC content almost unchanged (27.9% for the wild type
sequence and 28.6% after modification). The use of this modi-
fied gene enormously increased the expression of PfATP6, as
can be seen by immunodetection with anti-PfATP6 antibodies
(Fig. 3A). An aggregated form of PfATP6-BAD is also present
near 250 kDa. This is likely to be due to the trichloroacetic acid
precipitation used for the recovery of the total protein content;
this represents a drastic denaturing treatment of proteins that
can lead to their aggregation. When expressing PfATP6-BAD
from its wild type cDNA, several bands of proteins were
revealed in low amounts by anti-PfATP6 antibodies, generally
of lower size than the expected molecular mass of the mono-
meric protein. The presence of these lighter proteins can be
explained by the AT-rich composition of the PfATP6 gene as
FIGURE 2. Characteristics of purified SERCA1a E255L mutant; purification and ATPase activity. A, SDS-
PAGE followedbyCoomassie Blue staining. 7.5l of the eluted fractionwas loaded (E255L), and toquantify the
amount of SERCA-E255L in this sample, 100 and 400 ng of the wild type SERCA (SR) preparation were loaded.
M,molecularmassmarkers.B,Westernblot analysiswith anti-SERCA1aantibodies. 0.75l of theeluted fraction
(E255L) and 10 and 40 ng of the SERCA (SR) preparation were loaded. C, ATPase activities at 25 °C of SERCA1a
E255L in C12E8 (1 mg/ml) and C12E8/DOPC (0.2/0.05 mg/ml) and inhibition assays with thapsigargin and arte-
misinin. Purified SERCA1a E255L was diluted to 0.75 g/ml in the ATPase assay medium. The medium con-
tainedalso125MCa2andeitherC12E8 (1mg/ml) (experimentA) orC12E8/DOPC (0.2/0.05mg/ml) (experiments
B–E), and hydrolytic activity was monitored continuously with a coupled enzyme system by recording NADH
oxidation at 340 nm. The reactions were triggered by the addition of 5mMATP and stopped by the addition of
750 M EGTA. The inhibition effect of 1.5 M Tg was first checked (experiments A and B), and then the effect of
artemisinin was tested by preincubation of the protein with 10M artemisinin (experiment C) and 10 M Fe2 
10M artemisinin (experiment E). The effect of Fe2DMSOwas controlled by the addition of 10M Fe2 2
l of DMSO (experiment D). In this and subsequent figures, the initial decrease in NADH absorbance due to a
small amount of ADP in our ATP solution was removed.
FIGURE 3. Expression of PfATP6. A, on minimal medium. Shown is Western
blot analysis with anti-PfATP6 antibodies of the level of expression of PfATP6-
BAD expressed from the wild type cDNA of Pfatp6 (WT) and the codon-opti-
mizedone (CO). 10l of eachprotein solution after the expression assaywere
loaded, corresponding to 8 and 10g of proteins for theWT andCO samples,
respectively. 1 and 2 correspond to a signal acquisition of 14 and 2 min,
respectively. The arrow indicates the band corresponding to monomeric
PfATP6-BAD. B, on rich medium. Shown are analyses of fractions recovered
during the membrane preparation by Western blot analysis with avidin per-
oxidase. Fractions of 2 g of total proteins of crude extract (CE) and 1 g of
total proteins of LM and soluble fraction (S) were loaded. The arrows indicate
the biotinylated proteins endogenous of the yeast S. cerevisiae (acetyl-CoA
carboxylase (ACC), 250 kDa; pyruvate carboxylase (PC), 120 kDa;Arc1pprotein
(Arc1p), 45 kDa). C, analyses of these fractions by Western blot with anti-
PfATP6 antibodies. To quantify the amount of PfATP6-BAD in the LM fraction,
5, 10, 20, and 30 ng of purified PfATP6 supplemented with 1 g of total pro-
teins of light membrane fraction of yeast expressing SERCA1a were loaded.
SERCA Pumps and Artemisinin
26410 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 34•AUGUST 20, 2010
 at St G
eorge's, U
niversity of London on July 9, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
described for other plasmodial proteins expressed in S. cerevi-
siae (60) and in Pichia pastoris (60–62). Indeed, AT-rich
regions in a gene may form hairpins and mimic a termination
signal of transcription and therefore result in the synthesis of
truncated proteins. Consequently, we decided to use the opti-
mized construct for a large scale expression of PfATP6. Like the
mutant SERCA1a E255L, we were able to express PfATP6 at a
high level by the use of a fermentor for the yeast culture. With
this equipment, 50 g of wet cells were recovered per liter of
culture.
After preparation of the light yeast membrane fraction,
Western blot analyses with avidin peroxidase and anti-PfATP6
antibodies confirmed that PfATP6-BAD had been expressed
and had undergone in vivo biotinylation (see Fig. 3B). Because
PfATP6 is a SERCA-type protein with a location in the endo-
plasmic reticulum, we have focused on the light membrane
fraction (endoplasmic reticulum) in the next steps. The amount
of PfATP6-BAD contained in the LMs represents about 2% of
the total protein content as determined by Western blot
revealed with anti-PfATP6 antibodies (see Fig. 3C) and 8mg/li-
ter of culture. We also evaluated that about 30% of it was bio-
tinylated (2.4mg; data not shown) and therefore subject to puri-
fication by affinity chromatography. It can be noted that
naturally biotinylated yeast proteins (acetyl-CoA carboxylase
(ACC), 250 kDa; pyruvate carboxylase (PC), 120 kDa; Arc1p
protein (Arc1p), 45 kDa) aremainly eliminated with the soluble
fraction (see Fig. 3B). Nevertheless, because some of the soluble
proteins remain bound to the LM fraction, we included one or
two additional washing steps of themembranes with a highKCl
buffer that helped to remove the major part of the remaining
contaminant proteins before the
solubilization (see Fig. 4A, compare
lanes WS and WP). Then the mem-
branes were solubilized with DDM, a
mild detergent used successfully with
SERCA1a-BAD.The samedetergent/
protein ratio (3:1, w/w) was used
except that the protein and detergent
were 5 timesmore concentrated than
asdescribedpreviouslywithSERCA1a-
BAD (33). Under these conditions,
the solubilization was about 25% (see
Fig. 4A, compare lanesWP and SF).
Then 600 g of in vivo biotin-
ylated and solubilized PfATP6 was
added to 2 ml of streptavidin-
Sepharose resin. Among the non-
retained proteins, a part corre-
sponded to PfATP6-BAD (see Fig.
4A, lane FT). This could be due to
either exceeding the binding capac-
ity of the resin or an inappropriate
folding of the biotin acceptor
domain. The thrombin cleavage
between the sequence of PfATP6
and the biotinylated acceptor
domain was followed by a Coomas-
sie Blue staining gel (Fig. 4B) and
by immunodetection with anti-PfATP6 antibodies (Fig. 4C).
Then only PfATP6devoid of BAD tagwas eluted from the resin,
and the corresponding fractions were well purified (Fig. 4B,
lanes E1 and E2). An approximate concentration of 30 g/ml
was determined for the first elution and of 10 g/ml for the
second elution fraction. About 20% of PfATP6was still retained
on the resin (lane R*). The purity of the protein reached about
70% (the remaining 30% beingmainly due to thrombin) as eval-
uated from the color density of the Coomassie Blue-stained gel.
In conclusion, the purification procedure gave a total amount of
at least 160 g of purified PfATP6 starting from 1 liter of yeast
culture and therefore a yield of 26% compared with the amount
of biotinylated and solubilized PfATP6-BADadded to the resin.
Other plasmodial membrane proteins produced in P. pasto-
ris and purified over Ni2-nitrilotriacetic acid were generally
obtained in better yield (60–62). Despite our lower yield, we can
expect to recover PfATP6 with good functional properties by our
procedure because the yeast in vivobiotinylation that our protocol
implies tends to select properly folded proteins (34).
One possible point of concern is the possibility that yeast
expression of PfATP6 could induce molecular modifications of
the enzyme. Therefore, we performed matrix-assisted laser
desorption ionization time-of-flight mass spectrometry under
the conditions that we formerly designed for large membrane
proteins or their fragments (63). Briefly, after PfATP6 strepta-
vidin purification, we performed gel filtration high pressure liq-
uid chromatography to reduce the DDM content, and then the
protein was concentrated up to 2 mg/ml. Two controls were
performed; SERCA1a was purified from rabbit SR, and
SERCA1a was yeast-expressed and purified. In all three cases,
FIGURE4.PurificationofPfATP6onstreptavidin-Sepharose.A,Westernblot analysiswithavidinperoxidase
of thewashing, the solubilization, and thepurification stepsbefore thrombin cleavageof PfATP6. 0.5l of each
fraction was loaded (corresponding to 5 g of total proteins in the LM lane, for example). In order to remove
soluble biotinylated proteins (acetyl-CoA carboxylase (ACC), 250 kDa; pyruvate carboxylase (PC), 120 kDa;
Arc1p protein (Arc1p), 45 kDa), LM were diluted in washing buffer at 10 mg/ml and centrifuged. The resulting
supernatant (WS) was discarded, and the pellet was resuspended in solubilization buffer (WP) with the same
volume as the LM fraction and centrifuged. DDM was added, and solubilization was performed as described
under “Experimental Procedures.” The supernatant corresponding to the solubilized fraction (SF) was added to
the resin, and the flow-through fraction (FT) was removed. The resinwas thenwashedwith high salt buffer (HS)
and low salt buffer (LS). B, analyses of the resin and the eluted fractions by SDS-PAGE followed by Coomassie
Blue staining. Except for the molecular mass marker (M) and the SERCA (SR) fractions, 7.5 l of each fraction
were loaded. To check the action of thrombin in the cleavage of PfATP6-BAD (% of cleavage) and the efficiency
of elution, the resinbefore (R) andafter the first incubationwith thrombin (about 60%of cleavage,R1) andafter
the second one (about 90% of cleavage, R2) and also the resin after elution (R*) were analyzed. To quantify the
amountof PfATP6 recoveredafter the first (E1) and the second (E2) elution, 100, 200, and400ngof thewild type
SERCA (SR) preparationwere loaded. Thearrows indicatepotential nonspecific cleavagesof PfATP6.C, analyses
of the same fractions as inBbyWesternblotwith anti-PfATP6 antibodies.Only 0.75l were loaded in each lane.
Cleavage products of PfATP6 are hardly detectable (indicated by the arrows).
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the determined molecular mass was very close to the expected
molecular mass. In the case of PfATP6, we found a mass of
140,053 Da, whereas the expected mass is 139,994 Da. Under
similar conditions, rabbit SR SERCA1a gave 109,497 Da for an
expected mass of 109,489 Da, and yeast expressed SERCA1a
(which is slightly larger due to DNA construction (34)) gave
110,090 Da for an expected mass of 110,069 Da.5 Under these
conditions, the error associated with this type of measurement
is 0.05–0.1%, so that this excludes large modification, such as
partial proteolysis, glycosylations, etc.
Study of the Enzymatic Properties of the Soluble Purified
PfATP6—We first measured the specific ATPase activity of the
purified PfATP6 with the aid of the coupled enzyme assay as
described for SERCA1a E255L and in the presence of 1 mg/ml
C12E8 (data not shown) or 0.2mg/mlC12E8 (Fig. 5A, left). As can
be seen, the major part of ATP hydrolysis was stopped by the
addition of EGTA, indicative of calcium-dependent ATPase
activity. However, even at higher C12E8 concentrations (data
not shown), we observed a decrease of the hydrolytic rate
with time, suggesting that under these conditions with pure
detergent, the protein is inactivated during turnover. By the
addition of lipids (0.05 mg/ml of DOPC) together with 0.2
mg/ml C12E8, we were able to maintain a stable hydrolysis
rate of ATP that was still inhibited by EGTA (Fig. 5A, mid-
dle). A similar stabilization was obtained in the presence of
other lipids (1,2-dioleoyl-sn-glycero-3-phosphoserine, egg
yolk phosphatidylcholine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (data not shown)) or a lipid mixture
consisting of 48.4% DOPC, 43% 1-palmitoyl-2-oleoyl-sn-glyc-
ero-3-phosphoethanolamine, and 8.6% L--phosphatidylinosi-
tol) (Fig. 5A, right). The phospholipid composition of this mix-
ture was based on the membrane lipidic composition of
P. falciparum as described (64). At a C12E8/DOPC ratio of 0.2:
0.05mg/ml, the specific activity at 25 °C of the purified PfATP6
was 1.7 mol of hydrolyzed ATPmin1(mg of PfATP6)1,
which is about 30% of the activity of rabbit SERCA1a at this
temperature.
We then measured the rate of hydrolysis of ATP, carried out
by PfATP6, as a function of different calcium concentrations
(data not shown). PfATP6 is activated by a low concentration of
free Ca2 (pCa 7), and optimal activities are obtained in the
pCa interval 6–4 with a maximal stimulation around pCa 4.
Above this concentration, the activity is gradually inhibited by
the increasing amount of free Ca2. This pCa dependence pro-
file is also in agreement with the one described for rabbit
SERCA1a solubilized in C12E8 (51).
The ATPase activity of PfATP6 was also measured at differ-
ent pH (see supplemental Fig. S1). The pH optimumwas, at pH
7–7.5, 1.7 mol of hydrolyzed ATPmin1(mg of PfATP6)1,
whereas the activities at pH 6.5 and 8 were low. This is in agree-
ment with what was measured previously for SERCA1a (65).
Effect of Artemisinins—We then proceeded to test the effect of
artemisinin and somederivativesonPfATP6.By the additionof 10
M artemisinin, we were not able to detect any inhibition (what-
ever the temperature in the range of 20–37 °C) because 90% or
more of the activity was alwaysmeasured after the addition of this
drug to PfATP6 (Figs. 5B and 7 and supplemental Fig. S2A),
whereas under these conditions, PfATP6 was previously reported
to be completely inhibited (24, 26).We also tested the effects of 10
M artemisone or 10 M dihydroartemisinin (Fig. 5B) and lower
and higher concentrations of the artemisinins (1–100M for arte-
misininand1–500Mforartemisone)butwereneverable todem-
onstrate any effect on PfATP6-dependent Ca2-ATPase activity
(data not shown). Moreover, with a preincubation of 10 min with
artemisinin, we obtained the same result.
As was done with SERCA1a E255L, we also checked the effect
of artemisinin in the presence of iron (10M Fe2) by comparing
the effect with that obtained in the presence of iron alone (see
supplemental Fig. S2, B and C). This was carried out by preincu-
bating PfATP6with iron togetherwith artemisinin before trigger-5 D. Cardi, C. Marchand, and M. le Maire, unpublished results.
FIGURE 5.ATPase activities of purified PfATP6protein and effect of artemisinin drugs.A, activitywasmeasured at 25 °C and pH 7.5with 10g of proteins
in 2 ml of assay buffer (see legend to Fig. 1). The reaction was triggered by the addition of 5 mM ATP into the medium and stopped by the addition of a final
concentration of 750 M EGTA. The reactions were carried out in the presence of C12E8 (0.2 mg/ml), C12E8/DOPC (0.2/0.05 mg/ml), and C12E8/lipid mixture
(0.2/0.05mg/ml). B, the reactionswere performedwith 5g/ml purified PfATP6 at 25 °C in C12E8/DOPC (0.2/0.05mg/ml). Artemisinins were addedwith 2l of
a solution at 10mMprepared inDMSO. The effect of various artemisininswas tested by the addition of 10M (final concentrations) of the drugs during the ATP
hydrolysis of the enzyme.
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ing the reaction. On the other hand, the Ca2-ATPase activity as
well as the nonspecific activity was slightly decreased in the pres-
ence of Fe2. In addition, other artemisinin derivatives that were
also tested, including artemisone, which was also used in the
oocyte tests (26), and artesunate (see supplemental Fig. S2,D and
E), did not inhibit the ATPase activity of PfATP6 either.
Effect of SERCA Inhibitors—We then tested the effect of spe-
cific inhibitors of mammalian SERCA proteins (see Fig. 6),
including Tg, BHQ, and CPA, on PfATP6. These assays were
also performedwith the C12E8/DOPCmixture at 25 °C. A small
degree of inhibition was observed with 1.5 M Tg (data not
shown), and Ca2-dependent ATP hydrolysis became clearly
inhibited with 45 M Tg (Figs. 6 and 7). This means that
PfATP6 is significantly less sensitive than rabbit SERCA1a to
Tg because the latter is completely inhibited by concentrations
of Tg in the nanomolar range (66). These differences are well
correlated with the observations of Varotti et al. (67), who, on
parasites, found a similar difference in the maximum effect of
Tg between Plasmodium parasites and mammalian cells.
According to their results, for Plasmodium, 25 M Tg were
necessary to inhibit Ca2 release in the cytoplasm, whereas 500
nM Tg was sufficient for producing the same effect in mamma-
lian cells. Two other SERCA pump inhibitors were then
assayed.We observed that 20MBHQwas able to inhibit about
50% of the activity of PfATP6 (see Figs. 6 and 7) and that the
addition of 3MCPA resulted in an almost complete inhibition
of this activity (see Figs. 6 and 7), similar to what is observed
with rabbit SERCA1a and after expression of PfATP6 in
oocytes. The effect of these inhibitors, which was checked in
various conditions (detergent/lipid ratios, glycerol concentra-
tions), clearly indicates that PfATP6 is a high affinity target for
CPA in all of the conditions.6 Although less sensitive to Tg and
BHQ than rabbit SERCA1a, these results suggest that the puri-
fied PfATP6 qualitatively behaves the same way as a mamma-
lian SERCA protein. Vanadate, another P-type ATPase inhibi-
tor, was tested in a few experiments; close to 50% inhibitionwas
obtained at low vanadate concentration (100 M) and in the
absence of EGTA (data not shown; the exact experimental con-
ditions are described in the supplemental material).
Study of PfATP6 Enzymatic Activity in Membranes—One of
the differences between ourATPase assays and those donewith
oocytes is the presence of detergent. Consequently, because the
detergent could interfere with artemisinin drugs, the protein was
relipidated, and detergent was completely removed using Bio-
beads (Fig. 8A). Relipidated PfATP6 was then submitted to the
sametypeof inhibitionassaysat37 °Cbutwithoutanydetergent in
solution (Fig. 8B). Again, artemisone was not able to inhibit
PfATP6 even in the presence of iron. These results then conclu-
sively show that under our conditions, the purified PfATP6
enzyme is not inhibited by artemisinin and its derivatives.
Conclusions—Our work overcoming the obstacles of heter-
ologous expression of a membrane protein from an apicompl-
exan organism in yeast has provided the first opportunity to
study the functional properties of a purified SERCA of P. falci-
parum. This has revealed both similarities with (pH and pCa
profile) and some differences from (drug sensitivity) that of the
mammalian SERCA1a. This is not unexpected due to the
sequence differences and the presence of a number of cytoplas-
mic insertions in PfATP6, in particular in the N-domain (68).
Furthermore, the availability of a purified preparation has
allowed us to test in a direct way the evidence for interaction of
purified PfATP6with artemisinin arising from previous studies
after expression in the Xenopus oocyte membrane (24, 26).
However, neither by the addition of artemisinin, nor by the
further addition of Fe2 to induce radical formation was it
possible to observe an effect on the isolated system. We con-
clude that it is not possible to demonstrate an effect of arte-6 B. Arnou and J. V. Møller, unpublished results.
FIGURE6.Effect of inhibitorsof SERCA-typeproteinson theATPaseactiv-
ity of PfATP6. The reactionswere performedwith 5g/ml purified PfATP6 at
25 °C in C12E8/DOPC (0.2/0.05mg/ml). Theywere triggered by the addition of
5 mM ATP and stopped by the addition of 750 M EGTA. Inhibitors, diluted in
DMSO, were addedwith 2l of the correspondingmother solution. First, the
effect of DMSO on the activity of PfATP6 was monitored after the addition of
2l (DMSO0.1%) and 4l (DMSO0.6%) to PfATP6. Then the inhibitions of the
enzyme by thapsigargin (45 M), BHQ (20 M), and CPA (3 M) were tested.
FIGURE 7. Summary of the effect of specific inhibitors of SERCA and arte-
misinin drugs on theATPase activities of PfATP6measured as described
in the legends to Figs. 5 and 6. Each bar represents a minimum of three
experiments S.D. (error bars).
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misinin on PfATP6 ATPase activity and that the explanation
for the effect of artemisinin on the malarial parasite is prob-
ably more complex than originally thought. With respect to
the oocyte data, it should be taken into account that the
oocyte membranes represent a foreign and complex envi-
ronment with hundreds of other proteins being present
together with the expressed protein. The possibility cannot
be excluded that these and other putative proteins or prote-
olipid components could interact with PfATP6 and with the
tested drug and thereby affect ATPase activity. In oocyte
also, using the same tests based on measurements of ATPase
activity on membranes, Krishna and co-workers (26)
reported a strong inhibition of artemisinin on the SERCA1
E255L homology mutant with a Ki of 315 nM. However, we
demonstrate in the present paper that the Ca2-dependent
ATPase activity of this mutant in the endoplasmic reticulum
of COS cells is not affected by artemisinin. The same is true
for the purified mutant after yeast expression. Therefore, it
would appear to be an oocyte-specific artemisinin inhibition,
not extendable to other eukaryotic cells.
When trying to pinpoint the target of artemisinin or deriva-
tives, many puzzling facts come to mind. Clearly, in a cellular
context, artemisinin is affecting Ca2 homeostasis as demon-
strated, for example,withCa2-sensitive dyes, and it is nowalso
used to kill/induce apoptosis of cancer cells with a likely effect
onCa2mobilization (e.g. see Refs. 69–71). However, in P. fal-
ciparum, the rise of cytosolic Ca2 due to artesunate was
also observed after prior thapsigargin addition, suggesting
an intracellular target distinct from that of the endoplasmic
reticulum (69). In other experiments, artemisinin was shown
to induce swelling of mitochondria and to interfere with
mitochondrial electron transport in a yeast model (see Ref.
72 and references therein), and it was suggested that an
activated species of artemisinin could depolarize the mito-
chondrial membrane. However, this was not observed in
Toxoplasma exposed to artemisinin (21, 22). Because mito-
chondria are also a site of Ca2 storage, this may still be
related to the Ca2 homeostasis effect, but it is by no means
the only possible mechanism of action.
In other investigations of the target, it was shown that acti-
vated artemisinin formed covalent adducts with four major
membrane-associated proteins, but only one of these could be
classified, being a homolog of the translationally controlled
tumor protein with a still unknown function in parasites (73,
74). In future experiments, it will be important to reconcile
findings on the mechanisms of action of artemisinins obtained
in apicomplexan parasites and in genetic studies, with findings
from heterologous expression studies and with the present
results to reassess the target of artemisinin. The present data do
not support a direct action of artemisinins on PfATP6 (see also
Ref. 57), but we cannot exclude the possibility that artemisinin
may need some transformations before becoming active or that
it could act indirectly on PfATP6 after binding to another pro-
tein. Alternatively, the drug may act on other proteins, such as
Ca2 channels involved in Ca2 homeostasis. However, we
note that with our procedure for purification of PfATP6, we
have described a system with the potential for high throughput
screening with novel classes of inhibitors acting against a key
parasite transport protein.
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FIGURE 8. Effect of artemisone and thapsigargin on the ATPase activity of relipidated PfATP6. A, freeze-fracture electron microscopy analysis of relipi-
datedPfATP6with eggyolk phosphatidylcholine.Bar, 100nm. The sample is heterogenous and contains different lipid structures: vesicleswithonemembrane
protein (1), large membranous structures with dispersed proteins (2), multilamellar vesicles (3), and vesicles with membrane protein clusters (4). Each arrow
shows onemolecule of PfATP6. B, ATPase activities performed with 1.75 g/ml reconstituted PfATP6 at 37 °C. They were triggered by successive additions of
5mMATP and 100MCa2 and stopped by the addition of 750M EGTA. Artemisonewas addedwith 2l of solutions at 10 or 100mMprepared in DMSO. The
effects of artemisonewere testedbypreincubationof theprotein in150MEGTAwith10Martemisone (experiment B), 10MFe22l ofDMSO (experiment
C), 10 M Fe2  10 M artemisone (experiment D), or 10 M Fe2  100 M artemisone (experiment E) before starting the reaction. The effect of 15 M
thapsigargin (experiment F) was tested in the same conditions. The effect of DMSO and Fe2  DMSO was controlled by the addition of 2 l of DMSO
(experiment A) and 10 M Fe2 2 l DMSO (experiment C) to the protein before starting the reaction.
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